Oppenheimer reaffirmed their outperform rating on shares of Vor Biopharma (NYSE:VOR – Get Rating) in a research note issued to investors on Friday, Benzinga reports. Oppenheimer currently has a $18.00 price target on the stock. Oppenheimer also issued estimates for Vor Biopharma’s Q1 2023 earnings at ($0.39) EPS, Q2 2023 earnings at ($0.41) EPS and […]
Vor Biopharma (NYSE:VOR – Get Rating) had its price target trimmed by Robert W. Baird from $38.00 to $22.00 in a research report report published on Friday, The Fly reports. The brokerage currently has an outperform rating on the stock. VOR has been the topic of several other reports. HC Wainwright cut their target price […]
Vor Biopharma (NYSE:VOR – Get Rating) had its price objective reduced by HC Wainwright from $20.00 to $17.50 in a research note published on Friday, The Fly reports. They currently have a buy rating on the stock. Separately, JMP Securities reissued a market outperform rating and set a $12.00 target price on shares of Vor […]
Vor Biopharma (NYSE:VOR – Get Rating) had its price target lowered by Robert W. Baird from $38.00 to $22.00 in a report released on Friday morning, The Fly reports. The firm currently has an outperform rating on the stock. Several other equities research analysts also recently issued reports on VOR. HC Wainwright cut their target […]
Vor Biopharma (NYSE:VOR – Get Rating)‘s stock had its “outperform” rating restated by stock analysts at Oppenheimer in a note issued to investors on Friday, Benzinga reports. They presently have a $18.00 target price on the stock. Oppenheimer’s target price would indicate a potential upside of 208.75% from the company’s current price. Several other research […]